Anti-CD3 antibodies and methods of use thereof
The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
1. An isolated fully human monoclonal antibody, wherein said antibody has a heavy chain with three complementarity determining regions (CDRs) comprising a VH CDR1 comprising the amino acid sequence SYGMH (SEQ ID NO:33); a VH CDR2 comprising the amino acid sequence of IIWYDGSKKNYADSVKG (SEQ ID NO:34); and a VH CDR3 comprising the amino acid sequence of GTGYNWFDP (SEQ ID NO:35); and a light chain with three CDRs, comprising a VL CDR1 comprising the amino acid sequence of RASQSVSSSYLA (SEQ ID NO:36); a VL CDR2 comprising the amino acid sequence of GASSRAT (SEQ ID NO:37); and a VL CDR3 comprising the amino acid sequence of QQYGSSPIT (SEQ ID NO:38), wherein said antibody binds CD3.
2. The antibody of claim 1 , wherein said antibody further comprises the heavy chain variable amino acid sequence of SEQ ID NO: 10, and the light chain variable amino acid sequence of SEQ ID NOS: NO: 16.
3. The antibody of claim 1 , wherein said antibody is an IgG1 isotype.